RNA, U4 small nuclear 80, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-80P profile across patient tissues and cancer cell-line models. RNU4-80P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RNU4-80P is differentially expressed in 6, with the highest sampling consensus in ESCA. Additionally, RNU4-80P RNA expression shows 6,931 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, ESCA, and PDAC as cancer lineages where RNU4-80P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-80P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-80P survival associations across molecular data types. RNU4-80P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-80P RNA expression–survival associations across cancer types. High RNU4-80P expression shows unfavorable associations in KICH, LUAD, THCA, READ and KIRC, but favorable associations in SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RNU4-80P RNA expression.
This table summarizes RNU4-80P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-80P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-80P shows lower tumor expression in BLCA, KICH and ESCA and higher tumor expression in ESCA, STAD and LUSC. The ESCA box plot shows higher RNU4-80P RNA expression in tumor versus normal tissue (log2 FC = +2.050, t-test p = .022).
This table shows molecular features associated with RNU4-80P in patient tissues and cancer cell lines. In patient samples, RNU4-80P shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
